West Pharmaceutical Services, Inc. (WST)
Chart Events
Performance Outlook
| Previous Close | 340.98 |
| Open | 340.70 |
| Bid | 340.73 x 4000 |
| Ask | 342.83 x 1000 |
| Day's Range | 340.34 - 344.99 |
| 52 Week Range | 275.89 - 475.35 |
| Volume | |
| Avg. Volume | 415,359 |
| Market Cap | 25.364B |
| Beta (5Y Monthly) | 1.15 |
| PE Ratio (TTM) | 38.19 |
| EPS (TTM) | 8.97 |
| Earnings Date | Oct 26, 2022 - Oct 31, 2022 |
| Forward Dividend & Yield | 0.72 (0.21%) |
| Ex-Dividend Date | Jul 19, 2022 |
| 1y Target Est | 383.17 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for WST
Related Research
- West Pharmaceutical Services, IDaily – Vickers Top Buyers & Sellers for 08/04/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat11 days agoArgus Research
- PR Newswire
West Makes Minority Investment in Dublin-Based Latch Medical, a Developer of Vaccine and Biologics Delivery Platforms
West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced it has made a strategic investment in Latch Medical, a Dublin-based leader in next-generation vaccine and biologics delivery technology that is pioneering a new approach to intradermal delivery.
- Simply Wall St.
Here's Why We Think West Pharmaceutical Services (NYSE:WST) Is Well Worth Watching
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
- Motley Fool
West Pharmaceutical Services (WST) Q2 2022 Earnings Call Transcript
This morning, Eric Green and Bernard Birkett will review our financial results, provide an update on our business and present an update on our financial outlook for the remaining full year of 2022. There is a slide presentation that accompanies today's call and a copy of that presentation is available on the Investors section of our website.
